ArticleNature2020
B cells and tertiary lymphoid structures promote immunotherapy response.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,793 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1,793citing papers in PubMed, 1 pooled it
129.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,793 citing papers in PubMed, 1 synthesis or guideline pooled it, 2,551 citations in OpenAlex.
- Cross-ancestry meta-analysis identifies a GSTP1 variant in the polycyclic aromatic hydrocarbons metabolism-related pathway contributing to colorectal cancer susceptibility.Archives of toxicology · 2026Pooled it
- Deep learning-based CT model for non-invasive prediction of tertiary lymphoid structures in pancreatic cancer: a multicenter study with prospective validation in an immunochemotherapy cohort.Journal for immunotherapy of cancer · 2026Trial
- Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses.Journal for immunotherapy of cancer · 2026Trial
- Axitinib plus Avelumab in Recurrent/Metastatic Adenoid Cystic Carcinoma: Biomarker Analysis and Updated Results of the Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Efineptakin alfa (NT-I7) improves overall survival and induces immune niches in murine tumors.Genes & diseases · 2027Article
- B cells and humoral immunity in melanoma: regulatory and autoimmune-like features and implications for immunotherapy.Oncoimmunology · 2026Review
- Integrating tumor and immune cell transcriptomics to predict immune checkpoint inhibitor primary resistance in metastatic melanoma.Oncoimmunology · 2026Article
- Broad targeting of HPV E proteins by intratumoral and systemic B cell responses in HPV+ head and neck cancer.Oncoimmunology · 2026Article
- Tertiary lymphoid structures in gastrointestinal cancer: orchestrating tumour microenvironmental immune subcycles to elegantly amplify the cancer immunity cycle.Annals of medicine · 2026Review
- Cancer metastasis: biological mechanisms, therapeutic bottlenecks, and emerging interventions.Journal of hematology & oncology · 2026Review
- Neutrophil-epithelial niches arrest B-cell maturation in dysfunctional tertiary lymphoid structures of gastric cancer neoadjuvant immunochemotherapy.Journal for immunotherapy of cancer · 2026Article
- Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade.iScience · 2026Review
- Epigenetic regulation of humoral immunity: molecular mechanisms, diseases and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- CD8⁺ T Cell infiltration and spatial organization in cancer: mechanisms, barriers, and therapeutic strategies.Molecular biomedicine · 2026Review
- A mature tertiary lymphoid structure-associated spatial niche is inversely associated with ACC1-related lipid metabolism in neoadjuvant-treated hepatocellular carcinoma.Translational oncology · 2026Article
- Metabolic reprogramming in cancer-associated fibroblasts: orchestrating the tumor immune microenvironment and response to immune checkpoint blockade.Experimental hematology & oncology · 2026Review
- Stereotactic body radiation therapy enriches mediators of humoral immune activity in metastatic renal cell carcinoma.Journal for immunotherapy of cancer · 2026Article
- Dynamic Immune Responsiveness in Breast Cancer: Tumor Microenvironment Plasticity, Therapeutic Timing, and Clinical Translation.International journal of molecular sciences · 2026Review
1,733 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
60 authors at 12 institutions in 3 countries.
Beth A Helmink *Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. bhelmink@mdanderson.org.
Sangeetha M Reddy *Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianjun Gao *Department of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shaojun Zhang *Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rafet Basar *Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rohit ThakurDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Keren YizhakDepartment of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Moshe Sade-FeldmanDepartment of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Jorge BlandoDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Guangchun HanDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vancheswaran GopalakrishnanDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yuanxin XiDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hao ZhaoDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rodabe N AmariaDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hussein A TawbiDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alex P CogdillDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wenbin LiuDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Valerie S LeBleuDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fernanda G KugeratskiDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sapna PatelDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael A DaviesDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Patrick HwuDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeffrey E LeeDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeffrey E GershenwaldDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anthony LucciDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Reetakshi AroraDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Scott WoodmanDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Emily Z KeungDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pierre-Olivier GaudreauDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alexandre ReubenDepartment of Thoracic / Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christine N SpencerParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Elizabeth M BurtonDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lauren E HayduDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alexander J LazarDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Roberta ZapassodiImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Courtney W HudgensDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Deborah A LedesmaDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
SuFey OngNanostring Technologies, Seattle, WA, USA.
Michael BaileyNanostring Technologies, Seattle, WA, USA.
Sarah WarrenNanostring Technologies, Seattle, WA, USA.
Disha RaoDivision of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Oscar KrijgsmanDivision of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Elisa A RozemanDivision of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Daniel PeeperDivision of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Christian U BlankDivision of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Ton N SchumacherDivision of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Lisa H ButterfieldDepartments of Medicine, Surgery, Immunology and Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, USA.
Monika A ZelazowskaDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kevin M McBrideDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Raghu KalluriDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
James AllisonDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Florent PetitprezINSERM, Cordeliers Research Center, Team Cancer, Immune Control and Escape, Paris, France.
Wolf Herman FridmanINSERM, Cordeliers Research Center, Team Cancer, Immune Control and Escape, Paris, France.
Catherine Sautès-FridmanINSERM, Cordeliers Research Center, Team Cancer, Immune Control and Escape, Paris, France.
Nir HacohenDepartment of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Katayoun RezvaniDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Padmanee SharmaDepartment of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael T TetzlaffDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Linghua WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer A WargoDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USNanostring Technologies (United States) · USOncode Institute · NLThe Netherlands Cancer Institute · NLMassachusetts General Hospital · USCentre de Recherche des Cordeliers · FRInserm · FRMassachusetts Institute of Technology · USMemorial Sloan Kettering Cancer Center · USParker Institute for Cancer Immunotherapy · USUniversité Paris Cité · FRUniversity of Pittsburgh · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MThe RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2006 to 2025
$41.7MTRAINING OF ACADEMIC SURGICAL ONCOLOGISTST32CA009599 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Ashley M Holder, Jennifer A. Wargo · 1988 to 2026
$13.2MTRAINING FOR ACADEMIC ONCOLOGY/HEMATOLOGYT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, Courtney DiNardo · 1994 to 2026
$9.8MExosomes in Cancer TherapyR01CA213233 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 2017 to 2021
$2.0MEmploying mouse models to translate early detection of pancreas cancerR01CA195733 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU, PIWNICA-WORMS, DAVID · 2015 to 2017
$1.6MNCI NIH HHS CA195733NCI NIH HHS CA213233NCI NIH HHS P01 CA117969NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA195733NCI NIH HHS R01 CA213233NCI NIH HHS T32 CA009599NCI NIH HHS T32 CA009666
Abstract
Treatment with immune checkpoint blockade (ICB) has revolutionized cancer therapy. Until now, predictive biomarkers
Indexed as
ImmunotherapyBiomarkers, TumorB-LymphocytesCarcinoma, Renal CellCell Cycle CheckpointsClone CellsDendritic Cells, FollicularGene Expression Regulation, NeoplasticHumansImmunologic MemoryMass SpectrometryMelanomaNeoplasm MetastasisPhenotypePrognosisReceptors, ImmunologicBiomarkers, TumorReceptors, Immunologic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.